Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre‐trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin

AIMS: To assess whether people with type 2 diabetes transferring from higher basal insulin doses (> 20 units) to a starting dose of 16 units of insulin degludec/liraglutide (IDegLira) benefit from IDegLira with/without transient loss of glycaemic control. METHODS: Post hoc analysis of DUAL V and...

Descripción completa

Detalles Bibliográficos
Autores principales: Meneghini, L., Doshi, A., Gouet, D., Vilsbøll, T., Begtrup, K., Őrsy, P., Ranthe, M. F., Lingvay, I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003817/
https://www.ncbi.nlm.nih.gov/pubmed/31705547
http://dx.doi.org/10.1111/dme.14178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003817/
https://www.ncbi.nlm.nih.gov/pubmed/31705547
http://dx.doi.org/10.1111/dme.14178

Ejemplares similares